IBDEI1ZZ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33892,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,33892,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,33892,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,33893,0)
 ;;=D68.32^^131^1680^84
 ;;^UTILITY(U,$J,358.3,33893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33893,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,33893,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,33893,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,33894,0)
 ;;=C22.2^^131^1680^85
 ;;^UTILITY(U,$J,358.3,33894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33894,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,33894,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,33894,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,33895,0)
 ;;=D58.9^^131^1680^87
 ;;^UTILITY(U,$J,358.3,33895,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33895,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,33895,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,33895,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,33896,0)
 ;;=C81.99^^131^1680^88
 ;;^UTILITY(U,$J,358.3,33896,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33896,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33896,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,33896,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,33897,0)
 ;;=C81.90^^131^1680^89
 ;;^UTILITY(U,$J,358.3,33897,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33897,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,33897,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,33897,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,33898,0)
 ;;=D89.2^^131^1680^90
 ;;^UTILITY(U,$J,358.3,33898,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33898,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,33898,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,33898,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,33899,0)
 ;;=D05.12^^131^1680^91
 ;;^UTILITY(U,$J,358.3,33899,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33899,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,33899,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,33899,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,33900,0)
 ;;=D05.11^^131^1680^92
 ;;^UTILITY(U,$J,358.3,33900,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33900,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,33900,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,33900,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,33901,0)
 ;;=D05.10^^131^1680^93
 ;;^UTILITY(U,$J,358.3,33901,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33901,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,33901,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,33901,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,33902,0)
 ;;=D50.0^^131^1680^94
 ;;^UTILITY(U,$J,358.3,33902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33902,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,33902,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,33902,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,33903,0)
 ;;=D50.9^^131^1680^95
 ;;^UTILITY(U,$J,358.3,33903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33903,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,33903,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,33903,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,33904,0)
 ;;=C46.9^^131^1680^96
 ;;^UTILITY(U,$J,358.3,33904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33904,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,33904,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,33904,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,33905,0)
 ;;=C22.0^^131^1680^97
